ECA2
MCID: EPL132
MIFTS: 23

Epilepsy, Childhood Absence 2 (ECA2)

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Epilepsy, Childhood Absence 2

MalaCards integrated aliases for Epilepsy, Childhood Absence 2:

Name: Epilepsy, Childhood Absence 2 58 76 30 6
Epilepsy, Childhood Absence, Susceptibility to, 2 58 13 74
Eca2 58 76
Epilepsy, Childhood Absence, Type 2 41

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
onset in childhood (6-7 years)
seizures may remit in adolescence
high frequency of absence seizures (several per day)
seizures may persist into adulthood
accounts for 5-15% of childhood epilepsies
genetic heterogeneity (see eca1, )


HPO:

33
epilepsy, childhood absence 2:
Onset and clinical course childhood onset
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



External Ids:

OMIM 58 607681
MeSH 45 D004832
MedGen 43 C1843244
UMLS 74 C1843244

Summaries for Epilepsy, Childhood Absence 2

UniProtKB/Swiss-Prot : 76 Epilepsy, childhood absence 2: A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic- clonic seizures often develop in adolescence. Some individuals manifest febrile seizures. Absence seizures may either remit or persist into adulthood.

MalaCards based summary : Epilepsy, Childhood Absence 2, also known as epilepsy, childhood absence, susceptibility to, 2, is related to generalized epilepsy with febrile seizures plus, type 3, and has symptoms including absence seizures An important gene associated with Epilepsy, Childhood Absence 2 is GABRG2 (Gamma-Aminobutyric Acid Type A Receptor Gamma2 Subunit). The drugs Benzocaine and Nitroprusside have been mentioned in the context of this disorder. Related phenotypes are generalized tonic-clonic seizures and eeg with polyspike wave complexes

Description from OMIM: 607681

Related Diseases for Epilepsy, Childhood Absence 2

Diseases in the Childhood Absence Epilepsy family:

Epilepsy, Childhood Absence 1 Epilepsy, Childhood Absence 2
Epilepsy, Childhood Absence 6 Epilepsy, Childhood Absence 5

Diseases related to Epilepsy, Childhood Absence 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 generalized epilepsy with febrile seizures plus, type 3 11.2

Symptoms & Phenotypes for Epilepsy, Childhood Absence 2

Human phenotypes related to Epilepsy, Childhood Absence 2:

33
# Description HPO Frequency HPO Source Accession
1 generalized tonic-clonic seizures 33 HP:0002069
2 eeg with polyspike wave complexes 33 HP:0002392
3 febrile seizures 33 HP:0002373
4 eeg with spike-wave complexes (>3.5 hz) 33 HP:0010849
5 absence seizure 33 HP:0002121

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
absence seizures
febrile seizures may occur
generalized tonic-clonic seizures (often develop in adolescence)
eeg shows 3-4-hz spike and multispike slow wave complexes

Clinical features from OMIM:

607681

UMLS symptoms related to Epilepsy, Childhood Absence 2:


absence seizures

Drugs & Therapeutics for Epilepsy, Childhood Absence 2

Drugs for Epilepsy, Childhood Absence 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
2
Nitroprusside Approved, Investigational Phase 3 15078-28-1 11963622
3
Phentolamine Approved Phase 3 50-60-2 5775
4
tannic acid Approved Phase 3 1401-55-4
5
Esmolol Approved Phase 3 103598-03-4, 81147-92-4 59768
6
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
7
Clonidine Approved Phase 3 4205-90-7 2803
8
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
9
Hydralazine Approved Phase 3 86-54-4 3637
10
Enalaprilat Approved Phase 3 76420-72-9 6917719
11
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
12
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
13
Labetalol Approved Phase 3 36894-69-6 3869
14
Glycerol Approved, Investigational Phase 3 56-81-5 753
15
Tenecteplase Approved Phase 3 191588-94-0
16
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
17 Urapidil Investigational Phase 3 34661-75-1
18 Plasminogen Phase 3,Phase 2,Not Applicable
19 Fibrinolytic Agents Phase 3,Phase 2,Not Applicable
20 Tissue Plasminogen Activator Phase 3,Phase 2,Not Applicable
21 Neurotransmitter Agents Phase 3
22 Adrenergic Antagonists Phase 3
23 Vasodilator Agents Phase 3
24 Hormones Phase 3
25 calcium channel blockers Phase 3
26 Adrenergic beta-1 Receptor Antagonists Phase 3
27 Adrenergic alpha-Agonists Phase 3
28 Protective Agents Phase 3
29 HIV Protease Inhibitors Phase 3
30 Adrenergic alpha-1 Receptor Antagonists Phase 3
31 Analgesics Phase 3
32 Anti-Arrhythmia Agents Phase 3
33 Adrenergic Agents Phase 3
34 Adrenergic Agonists Phase 3
35 Peripheral Nervous System Agents Phase 3
36 Sympathomimetics Phase 3
37 Serotonin Receptor Agonists Phase 3
38 Adrenergic alpha-Antagonists Phase 3
39 Angiotensin-Converting Enzyme Inhibitors Phase 3
40 Calcium, Dietary Phase 3
41 Sympatholytics Phase 3
42 Autonomic Agents Phase 3
43 Adrenergic alpha-2 Receptor Agonists Phase 3
44
protease inhibitors Phase 3
45 Serotonin Agents Phase 3
46 Adrenergic beta-Antagonists Phase 3
47 Antihypertensive Agents Phase 3
48
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
49
Lactitol Investigational Phase 2 585-86-4, 585-88-6 493591
50 Fingolimod Hydrochloride Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) Completed NCT01422616 Phase 3 Low-dose rtPA;Standard-dose rtPA
2 Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis Recruiting NCT02814409 Phase 3 Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase;Intravenous Tenecteplase
3 Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke Unknown status NCT02956200 Phase 2 Fingolimod
4 Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA Completed NCT01614080
5 Pre-stroke Cognitive Status and Thrombolytic Therapy Completed NCT01713491
6 Pragmatic Ischaemic Stroke Thrombectomy Evaluation Terminated NCT01745692 Not Applicable Intravenous rtPA

Search NIH Clinical Center for Epilepsy, Childhood Absence 2

Genetic Tests for Epilepsy, Childhood Absence 2

Genetic tests related to Epilepsy, Childhood Absence 2:

# Genetic test Affiliating Genes
1 Epilepsy, Childhood Absence 2 30 GABRG2

Anatomical Context for Epilepsy, Childhood Absence 2

Publications for Epilepsy, Childhood Absence 2

Variations for Epilepsy, Childhood Absence 2

UniProtKB/Swiss-Prot genetic disease variations for Epilepsy, Childhood Absence 2:

76
# Symbol AA change Variation ID SNP ID
1 GABRG2 p.Arg82Gln VAR_014265 rs121909673

ClinVar genetic disease variations for Epilepsy, Childhood Absence 2:

6 (show top 50) (show all 88)
# Gene Variation Type Significance SNP ID Assembly Location
1 GABRG2 NM_000816.3(GABRG2): c.316G> A (p.Ala106Thr) single nucleotide variant Pathogenic/Likely pathogenic rs796052505 GRCh37 Chromosome 5, 161522557: 161522557
2 GABRG2 NM_000816.3(GABRG2): c.316G> A (p.Ala106Thr) single nucleotide variant Pathogenic/Likely pathogenic rs796052505 GRCh38 Chromosome 5, 162095551: 162095551
3 GABRG2 NM_000816.3(GABRG2): c.967C> T (p.Arg323Trp) single nucleotide variant Uncertain significance rs796052510 GRCh38 Chromosome 5, 162149152: 162149152
4 GABRG2 NM_000816.3(GABRG2): c.967C> T (p.Arg323Trp) single nucleotide variant Uncertain significance rs796052510 GRCh37 Chromosome 5, 161576158: 161576158
5 GABRG2 NM_000816.3(GABRG2): c.1088G> A (p.Arg363Gln) single nucleotide variant Uncertain significance rs780199000 GRCh38 Chromosome 5, 162149273: 162149273
6 GABRG2 NM_000816.3(GABRG2): c.1088G> A (p.Arg363Gln) single nucleotide variant Uncertain significance rs780199000 GRCh37 Chromosome 5, 161576279: 161576279
7 GABRG2 NM_000816.3(GABRG2): c.1212C> T (p.Tyr404=) single nucleotide variant Benign/Likely benign rs749951528 GRCh38 Chromosome 5, 162153176: 162153176
8 GABRG2 NM_000816.3(GABRG2): c.1212C> T (p.Tyr404=) single nucleotide variant Benign/Likely benign rs749951528 GRCh37 Chromosome 5, 161580182: 161580182
9 GABRG2 NM_000816.3(GABRG2): c.1336C> T (p.Arg446Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs796052515 GRCh38 Chromosome 5, 162153300: 162153300
10 GABRG2 NM_000816.3(GABRG2): c.1336C> T (p.Arg446Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs796052515 GRCh37 Chromosome 5, 161580306: 161580306
11 GABRG2 NM_000816.3(GABRG2): c.409T> C (p.Leu137=) single nucleotide variant Benign rs200828542 GRCh38 Chromosome 5, 162097719: 162097719
12 GABRG2 NM_000816.3(GABRG2): c.409T> C (p.Leu137=) single nucleotide variant Benign rs200828542 GRCh37 Chromosome 5, 161524725: 161524725
13 GABRG2 NM_000816.3(GABRG2): c.245G> A (p.Arg82Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs121909673 GRCh37 Chromosome 5, 161520971: 161520971
14 GABRG2 NM_000816.3(GABRG2): c.245G> A (p.Arg82Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs121909673 GRCh38 Chromosome 5, 162093965: 162093965
15 GABRG2 GABRG2, IVS6DS, T-G, +2 single nucleotide variant Pathogenic,risk factor
16 GABRG2 NM_000816.3(GABRG2): c.354G> A (p.Ala118=) single nucleotide variant Benign/Likely benign rs61735412 GRCh37 Chromosome 5, 161524670: 161524670
17 GABRG2 NM_000816.3(GABRG2): c.354G> A (p.Ala118=) single nucleotide variant Benign/Likely benign rs61735412 GRCh38 Chromosome 5, 162097664: 162097664
18 GABRG2 NM_000816.3(GABRG2): c.717A> G (p.Gln239=) single nucleotide variant Benign/Likely benign rs78261481 GRCh37 Chromosome 5, 161530980: 161530980
19 GABRG2 NM_000816.3(GABRG2): c.717A> G (p.Gln239=) single nucleotide variant Benign/Likely benign rs78261481 GRCh38 Chromosome 5, 162103974: 162103974
20 GABRG2 NM_000816.3(GABRG2): c.360G> A (p.Thr120=) single nucleotide variant Benign rs77298346 GRCh38 Chromosome 5, 162097670: 162097670
21 GABRG2 NM_000816.3(GABRG2): c.360G> A (p.Thr120=) single nucleotide variant Benign rs77298346 GRCh37 Chromosome 5, 161524676: 161524676
22 GABRG2 NM_000816.3(GABRG2): c.530delG (p.Arg177Glnfs) deletion Pathogenic rs878854144 GRCh38 Chromosome 5, 162097840: 162097840
23 GABRG2 NM_000816.3(GABRG2): c.530delG (p.Arg177Glnfs) deletion Pathogenic rs878854144 GRCh37 Chromosome 5, 161524846: 161524846
24 GABRG2 NM_000816.3(GABRG2): c.789T> G (p.Ser263=) single nucleotide variant Likely benign rs754514348 GRCh38 Chromosome 5, 162142183: 162142183
25 GABRG2 NM_000816.3(GABRG2): c.789T> G (p.Ser263=) single nucleotide variant Likely benign rs754514348 GRCh37 Chromosome 5, 161569189: 161569189
26 GABRG2 NM_000816.3(GABRG2): c.691G> A (p.Asp231Asn) single nucleotide variant Uncertain significance rs773065895 GRCh37 Chromosome 5, 161530954: 161530954
27 GABRG2 NM_000816.3(GABRG2): c.691G> A (p.Asp231Asn) single nucleotide variant Uncertain significance rs773065895 GRCh38 Chromosome 5, 162103948: 162103948
28 GABRG2 NM_000816.3(GABRG2): c.1296G> A (p.Gly432=) single nucleotide variant Conflicting interpretations of pathogenicity rs150727562 GRCh37 Chromosome 5, 161580266: 161580266
29 GABRG2 NM_000816.3(GABRG2): c.1296G> A (p.Gly432=) single nucleotide variant Conflicting interpretations of pathogenicity rs150727562 GRCh38 Chromosome 5, 162153260: 162153260
30 GABRG2 NM_000816.3(GABRG2): c.135C> T (p.Asp45=) single nucleotide variant Conflicting interpretations of pathogenicity rs375308385 GRCh38 Chromosome 5, 162093855: 162093855
31 GABRG2 NM_000816.3(GABRG2): c.135C> T (p.Asp45=) single nucleotide variant Conflicting interpretations of pathogenicity rs375308385 GRCh37 Chromosome 5, 161520861: 161520861
32 GABRG2 NM_000816.3(GABRG2): c.954C> T (p.Leu318=) single nucleotide variant Likely benign rs749531013 GRCh37 Chromosome 5, 161576145: 161576145
33 GABRG2 NM_000816.3(GABRG2): c.954C> T (p.Leu318=) single nucleotide variant Likely benign rs749531013 GRCh38 Chromosome 5, 162149139: 162149139
34 GABRG2 NM_000816.3(GABRG2): c.1230C> T (p.Asp410=) single nucleotide variant Benign/Likely benign rs113085352 GRCh38 Chromosome 5, 162153194: 162153194
35 GABRG2 NM_000816.3(GABRG2): c.1230C> T (p.Asp410=) single nucleotide variant Benign/Likely benign rs113085352 GRCh37 Chromosome 5, 161580200: 161580200
36 GABRG2 NM_000816.3(GABRG2): c.269C> T (p.Thr90Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1057520498 GRCh37 Chromosome 5, 161522510: 161522510
37 GABRG2 NM_000816.3(GABRG2): c.269C> T (p.Thr90Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1057520498 GRCh38 Chromosome 5, 162095504: 162095504
38 GABRG2 NC_000005.10: g.(?_162101235)_(162155539_?)dup duplication Uncertain significance GRCh38 Chromosome 5, 162101235: 162155539
39 GABRG2 NC_000005.10: g.(?_162101235)_(162155539_?)dup duplication Uncertain significance GRCh37 Chromosome 5, 161528241: 161582545
40 GABRG2 NM_000816.3(GABRG2): c.71C> A (p.Thr24Lys) single nucleotide variant Uncertain significance rs1060501891 GRCh37 Chromosome 5, 161495076: 161495076
41 GABRG2 NM_000816.3(GABRG2): c.71C> A (p.Thr24Lys) single nucleotide variant Uncertain significance rs1060501891 GRCh38 Chromosome 5, 162068070: 162068070
42 GABRG2 NM_000816.3(GABRG2): c.36A> T (p.Ser12=) single nucleotide variant Likely benign rs762058667 GRCh37 Chromosome 5, 161495041: 161495041
43 GABRG2 NM_000816.3(GABRG2): c.36A> T (p.Ser12=) single nucleotide variant Likely benign rs762058667 GRCh38 Chromosome 5, 162068035: 162068035
44 GABRG2 NM_000816.3(GABRG2): c.583C> A (p.His195Asn) single nucleotide variant Uncertain significance rs981863613 GRCh37 Chromosome 5, 161528275: 161528275
45 GABRG2 NM_000816.3(GABRG2): c.583C> A (p.His195Asn) single nucleotide variant Uncertain significance rs981863613 GRCh38 Chromosome 5, 162101269: 162101269
46 GABRG2 NM_000816.3(GABRG2): c.942A> G (p.Thr314=) single nucleotide variant Likely benign rs377502016 GRCh37 Chromosome 5, 161576133: 161576133
47 GABRG2 NM_000816.3(GABRG2): c.942A> G (p.Thr314=) single nucleotide variant Likely benign rs377502016 GRCh38 Chromosome 5, 162149127: 162149127
48 GABRG2 NM_000816.3(GABRG2): c.1025delG (p.Cys342Phefs) deletion Likely pathogenic rs1060501889 GRCh37 Chromosome 5, 161576216: 161576216
49 GABRG2 NM_000816.3(GABRG2): c.1025delG (p.Cys342Phefs) deletion Likely pathogenic rs1060501889 GRCh38 Chromosome 5, 162149210: 162149210
50 GABRG2 NM_000816.3(GABRG2): c.1171A> G (p.Met391Val) single nucleotide variant Likely benign rs753097258 GRCh37 Chromosome 5, 161580141: 161580141

Expression for Epilepsy, Childhood Absence 2

Search GEO for disease gene expression data for Epilepsy, Childhood Absence 2.

Pathways for Epilepsy, Childhood Absence 2

GO Terms for Epilepsy, Childhood Absence 2

Sources for Epilepsy, Childhood Absence 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....